Format

Send to

Choose Destination
See comment in PubMed Commons below
Ann Oncol. 2012 Sep;23(9):2215-22. doi: 10.1093/annonc/mds009. Epub 2012 Feb 22.

Bone matters in lung cancer.

Author information

1
Clinical Division of Oncology, Department of Medicine I, Medical University of Vienna General Hospital, Vienna, Austria. thomas.brodowicz@meduniwien.ac.at

Abstract

BACKGROUND:

Bone metastases are a significant and undertreated clinical problem in patients with advanced lung cancer.

DESIGN:

We reviewed the incidence of bone metastases and skeletal-related events (SREs) in patients with lung cancer and examined the burden on patients' lives and on health care systems. Available therapies to improve survival and lessen the impact of SREs on quality of life (QoL) were also investigated.

RESULTS:

Bone metastases are common in lung cancer; however, owing to short survival times, data on the incidences of SREs are limited. As with other cancers, the costs associated with treating SREs in lung cancer are substantial. Bisphosphonates reduce the frequency of SREs and improve measures of pain and QoL in patients with lung cancer; however, nephrotoxicity is a common complication of therapy. Denosumab, a recently approved bone-targeted therapy, is superior to zoledronic acid in increasing the time to first on-study SRE in patients with solid tumours, including lung cancer. Additional roles of bone-targeted therapies beyond the prevention of SREs are under investigation.

CONCLUSIONS:

With increasing awareness of the consequences of SREs, bone-targeted therapies may play a greater role in the management of patients with lung cancer, with the aim of delaying disease progression and preserving QoL.

PMID:
22357445
PMCID:
PMC3425370
DOI:
10.1093/annonc/mds009
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems Icon for PubMed Central
    Loading ...
    Support Center